hematolog
patient
immunosuppress
caus
hematolog
diseas
treatment
usual
predict
sever
type
infect
neutropenia
predispos
sever
bacteri
infect
prolong
fungal
infect
impair
tcell
function
increas
risk
fungal
viral
infect
besid
knowledg
patient
immun
statu
local
resist
pattern
frequenc
extend
spectrum
betalactamas
esbl
produc
enterobacteriacea
methillicinresist
staphylococcu
aureu
mrsa
import
decid
empir
antimicrobi
therapi
import
diagnost
principl
immunosuppress
patient
go
bug
place
infect
use
invas
procedur
often
bronchoalveolar
lavag
bal
biopsi
prevent
infect
hematolog
patient
consist
antimicrobi
prophylaxi
prevent
exposur
infecti
agent
immun
prophylaxi
vaccin
immun
globulin
studi
antibacteri
prophylaxi
perform
fluoroquinolon
although
risk
neutropen
fever
reduc
effect
outcom
variabl
use
controversi
due
increas
rate
resist
antibacteri
prophylaxi
use
reserv
highrisk
patient
antifung
antivir
prophylaxi
regimen
discuss
section
deal
specif
pathogen
chapter
prevent
measur
describ
tabl
aepidemiolog
neutropen
fever
usual
defin
singl
temperatur
measur
temperatur
sustain
period
patient
anc
common
patient
hematolog
malign
occur
patient
chemotherapyassoci
neutropeniain
approxim
episod
diagnosi
establish
ie
fever
unknown
origin
fuo
wherea
clinic
document
infect
microbiolog
document
infect
diagnos
around
episod
bloodstream
infect
constitut
vast
major
microbiolog
document
infect
epidemiolog
bloodstream
infect
differ
center
gener
slight
domin
gramneg
enter
bacteria
e
coli
k
pneumonia
p
aeruginosa
gramposit
pathogen
coagulaseneg
staphylococci
viridan
streptococci
e
faecium
antimicrobi
resist
rapidli
increas
among
gramneg
gramposit
isol
importantli
extend
esbl
product
enterobacteriaceaeth
allov
mortal
low
around
due
low
mortal
patient
fuo
patient
document
infect
report
mortal
rate
consider
higher
around
patient
lung
infiltr
sever
sepsi
patient
septic
shock
bdiagnost
care
clinic
examin
perform
daili
identifi
possibl
infect
focus
detect
clinic
deterior
focus
easili
overlook
includ
dental
infect
perian
infectionsblood
cultur
taken
central
cathet
peripher
simultan
make
possibl
identifi
catheterrel
bloodstream
infect
see
section
crbsi
total
blood
volum
least
ml
ie
four
bottl
reach
accept
sensitivityoth
cultur
depend
clinic
sign
infect
possibl
specimen
includ
sputum
urin
skin
stool
sampl
clostridium
difficil
pcr
respiratori
virus
perform
sever
immunocompromis
patient
respiratori
symptom
especi
influenza
season
pcr
virus
usual
part
initi
workupin
patient
respiratori
symptom
thorac
ct
scan
perform
chest
xray
meaning
neutropen
patient
low
sensit
specif
see
also
section
pneumonia
bal
perform
ct
scan
show
lung
infiltr
tabl
section
pneumonia
new
skin
lesionsnodul
biopsi
sent
microscopi
cultur
fungal
pcr
consideredcantimicrobi
therapi
empir
therapi
potenti
lifethreaten
infect
treatment
must
alway
initi
promptli
infect
gramneg
bacteria
associ
high
mortal
empir
therapi
must
therefor
alway
includ
broad
gramneg
coverag
includ
pseudomona
speci
firsthand
treatment
option
present
tabl
vancomycin
ad
routin
empir
treatment
studi
clearli
shown
impact
mortal
oral
antimicrobi
treatment
may
given
start
select
lowrisk
patient
tabl
target
therapi
empir
therapi
deescal
target
therapi
microbiolog
document
infect
patient
becom
afebril
neutropen
patient
fever
usual
sign
new
infect
miss
antimicrobi
coverag
narrow
target
treatment
persist
febril
neutropen
patient
durat
therapi
patient
fuo
still
neutropen
h
without
fever
patient
fuo
nonneutropen
resolut
fever
patient
microbiolog
clinic
document
infect
fuo
except
total
durat
therapi
shorter
normal
treatment
durat
nonneutropen
patient
diagnosi
dneutropen
fever
despit
h
treatment
broadspectrum
antibiot
manag
algorithm
present
fig
new
diagnost
workup
neg
patient
stabl
ie
deterior
usual
chang
therapi
necessaryif
neutropen
fever
continu
new
cycl
diagnost
workup
initiatedaddit
empir
vancomycin
stabl
patient
shown
decreas
mortal
durat
fever
avoidedif
patient
deterior
antimicrobi
therapi
must
chang
includ
even
broader
coverag
carbapenem
meropenem
imipenemcilastatin
prescrib
alreadi
given
empir
antifung
therapi
initi
see
section
empir
antifung
therapi
addit
amikacin
andor
vancomycin
consid
aepidemiolog
respiratori
symptom
andor
new
lung
infiltr
frequent
patient
hematolog
diseas
patient
receiv
treatment
acut
leukemia
may
affect
associ
mortal
etiolog
often
depend
underli
immunosuppress
tabl
mani
case
etiolog
establishednoninfecti
reason
new
infiltr
consid
includ
alveolar
bleed
heart
failur
infiltr
hematolog
malign
organ
pneumonia
immun
reconstitut
syndrom
damag
chemotherapi
radiationbdiagnost
clinic
present
usual
fever
andor
respiratori
symptom
cough
dyspnea
hemoptysi
andor
impair
oxygenationfind
physic
examin
includ
tachypnea
impair
oxygen
lung
crepitationsa
thorac
ct
scan
perform
earli
patient
acut
leukemia
tcell
suppress
experienc
respiratori
symptom
earli
detect
lung
infiltr
indic
invas
mold
diseas
pneumocysti
jirovecii
pneumonia
pcp
lead
earli
institut
antimicrobi
treatment
shown
result
improv
surviv
convent
chest
xray
limit
valu
patient
hematolog
diseas
especi
neutropen
low
sensit
specif
compar
ct
extent
microbiolog
sampl
depend
sever
pneumonia
grade
immunosuppress
tabl
bal
often
requir
establish
microbiolog
diagnos
consid
earli
patient
acut
leukemia
tcell
suppress
lung
infiltr
tabl
bal
alway
perform
unless
contraind
respons
initi
empir
antimicrobi
treatmentcoagulaseneg
staphylococci
enterococci
candida
speci
gener
etiolog
relev
lung
infiltr
even
found
bal
culturectreat
empir
treatment
neutropen
patient
andor
nosocomi
pneumonia
empir
treatment
includ
adequ
pseudomona
coverag
besid
coverag
gramneg
enter
bacteria
pneumonia
h
influenza
aureu
suitabl
option
includ
piperacillintazobactam
cefepim
meropenem
imipenemcilastatin
nonneutropen
patient
communityacquir
pneumonia
cefotaximeceftriaxon
reason
firsthand
altern
admit
hospit
amoxicillinclavulan
levofloxacin
treat
outpati
patient
tcell
suppress
addit
trimethoprimsulfamethoxazol
tmpsmx
empir
treatment
pcp
consid
prophylaxi
target
treatment
target
therapi
outlin
tabl
section
fungal
infect
viral
infect
breakthrough
infect
respons
empir
treatment
new
thorac
ct
scan
perform
identifi
progress
infiltr
new
infiltr
compat
invas
mold
infect
pcp
also
use
decid
lobe
bal
perform
bal
alway
perform
contraind
tabl
chang
meropenemimipenem
receiv
piperacillintazobactam
cefepim
ceftazidim
consid
addit
voriconazol
empir
treatment
invas
aspergillosi
patient
receiv
moldact
prophylaxi
lipid
formul
amphotericin
b
coverag
mold
infect
patient
receiv
mold
prophylaxi
consid
ad
fluoroquinolon
alreadi
prescrib
prophylaxi
consid
ad
highdos
tmpsmx
risk
pcp
andor
stenotrophomona
maltophilia
aepidemiolog
differ
definit
crbsi
exist
common
clinic
use
definit
growth
central
blood
cultur
least
h
peripher
blood
cultur
blood
cultur
cathet
tip
cultur
growth
organ
crbsi
wellrecogn
complic
hematolog
patient
report
incid
till
per
cathet
day
caus
organ
often
coagulaseneg
staphylococci
follow
staphylococcu
aureu
candida
speci
seldom
gramneg
enter
bacteria
klebsiella
pneumonia
pseudomona
aeruginosaappropri
prevent
measur
import
minim
crbsi
includ
educ
healthcar
personnel
handl
central
venou
cathet
cvc
applic
asept
bundl
insert
use
cvc
addit
assess
necess
cvc
made
routin
prompt
remov
need
bdiagnost
often
clinic
sign
fever
sometim
accompani
sign
local
infect
insert
site
tunnelblood
cultur
simultan
drawn
peripher
central
cathet
prefer
one
set
blood
cultur
per
lumenif
differenti
time
posit
dtp
h
favor
blood
cultur
drawn
cvc
crbsi
definit
fulfil
diagnos
catheterrel
infect
also
made
without
posit
blood
cultur
undisput
sign
infect
erythema
swollen
pain
cathet
tunnel
port
pocketin
case
posit
central
blood
cultur
organ
known
caus
crbsi
neg
peripher
blood
cultur
local
sign
infect
catheterrel
infect
suspect
proven
diagnost
algorithm
scenario
outlin
fig
cathet
remov
togeth
target
antimicrobi
therapi
remain
mainstay
treatment
crbsi
remov
alway
perform
septic
hypotens
patient
patient
complic
crbsi
tunnel
port
infect
crbsi
caus
candida
speci
vancomycin
ad
septic
hypotens
patient
suspect
crbsi
andor
local
sign
infect
tunnel
infect
port
abscess
cellul
around
insert
sitein
cbrsi
caus
pseudomona
aeruginosa
staphylococcu
aureu
remov
cathet
associ
lower
relaps
rate
better
outcom
perform
routinelyin
cbrsi
caus
gram
neg
pseudomona
antibioticlock
therapi
tri
remov
cathet
feasiblein
crb
coagulaseneg
staphylococci
local
sign
infect
cathet
often
retain
use
antibioticlock
therapyantibioticlock
therapi
involv
instal
high
concentr
antibiot
caus
microb
suscept
cathet
lumen
solut
left
lumen
without
interrupt
least
h
per
h
longer
possibl
use
cathet
retain
strategi
day
combin
system
therapi
antibioticlock
therapi
usual
recommend
blood
cultur
becom
neg
iv
therapi
may
switch
oralif
cathet
remov
sign
local
metastat
infect
treatment
durat
usual
day
except
staphylococcu
aureu
day
candida
speci
day
first
neg
blood
cultur
typhliti
potenti
seriou
complic
neutropen
patient
character
fever
abdomin
pain
thicken
cecum
adjac
ileum
bthe
pathogenesi
involv
intestin
damag
associ
neutropenia
mucos
follow
microbi
invas
inflamm
ulcerationcth
report
incid
vari
depend
definit
intens
chemotherapi
patient
hematolog
malign
patient
aml
dultrasound
ct
scan
show
bowel
wall
thicken
neutropen
patient
fever
abdomin
pain
diagnosticeblood
cultur
clostridium
difficil
assay
perform
antimicrobi
treatment
cover
gramneg
includ
pseudomona
aeruginosa
anaerob
institut
promptli
suitabl
option
includ
monotherapi
meropenem
imipenemcilastatin
piperacillintazobactam
combin
cefepim
metronidazoleftransloc
candida
speci
may
occur
empir
treatmentprophylaxi
candidaact
agent
fluconazol
echinocandin
consideredgbowel
rest
gcsf
shorten
durat
neutropenia
may
consid
evid
effect
lackinghsurgeri
avoid
unless
absolut
necessari
perfor
massiv
bleed
aempir
preemptiv
antifung
therapi
epidemiolog
prolong
neutropen
fever
despit
broadspectrum
antibiot
therapi
common
empir
antifung
therapi
base
indic
lead
administr
antifung
around
one
third
neutropen
patient
howev
major
patient
invas
fungal
diseas
ifd
indiscrimin
empir
antifung
therapi
thu
expos
patient
unnecessari
potenti
harm
drugsth
incid
ifd
approxim
highrisk
patient
receiv
candidaact
prophylaxi
amlmd
patient
receiv
remissionintend
chemotherapi
patient
receiv
moldact
prophylaxi
usual
posaconazol
voriconazol
report
frequenc
breakthrough
ifd
consider
lower
patient
anticip
short
period
neutropenia
day
low
risk
ifd
especi
receiv
candidaact
prophylaxi
diagnost
initi
diagnost
workup
includ
blood
cultur
thorac
ct
scan
biomark
blood
serum
usual
galactomannan
gm
andor
betaglucan
see
section
invas
aspergillosi
invas
candida
infect
mani
commerci
blood
cultur
system
good
sensit
candida
speci
concomit
bacteremia
possibl
except
candida
glabrata
thu
suspicion
invas
candida
infect
high
concomit
bacteremia
suspect
blood
cultur
better
sensit
yeast
mycosi
bottl
includ
case
pulmonari
infiltr
bal
perform
tabl
candidaact
prophylaxi
administ
ct
scan
abdomen
look
sign
hepatosplen
candidiasi
may
consid
new
skin
lesionnodul
biopsi
sent
microscopi
cultur
pcr
treatment
firstlin
option
includ
lipid
formul
amphotericin
b
echinocandin
voriconazol
best
choic
treatment
patient
suspect
breakthrough
infect
moldact
treatment
evalu
clinic
trial
switch
anoth
drug
class
recommend
patient
receiv
moldact
azol
chang
lipid
formul
amphotericin
b
logic
choic
give
broad
coverag
mold
infect
aspergillosi
time
empir
antifung
treatment
depend
choic
strategi
empir
approach
antifung
treatment
initi
h
neutropen
fever
despit
broadspectrum
antibiot
even
sign
find
suggest
ifd
discuss
approach
expos
mani
patient
unnecessari
potenti
harm
treatment
recommendedin
preemptiv
approach
patient
screen
bloodplasma
two
three
time
per
week
one
biomark
often
gm
biomark
becom
posit
thorac
ct
scan
perform
infiltr
present
bal
perform
empir
antifung
therapi
start
patient
neg
ct
scan
screen
biomark
continu
antifung
start
biomark
becom
posit
procedur
thorac
ct
scan
repeat
studi
shown
approach
significantli
reduc
use
antifung
without
reduc
overal
surviv
although
frequenc
diagnos
ifd
slightli
higher
empir
arm
diagnost
approach
biomark
thorac
ct
scan
perform
highrisk
patient
neutropen
fever
day
despit
broadspectrum
antibiot
infiltr
found
bal
perform
biomark
ct
scan
neg
patient
stabl
empir
antifung
therapi
withheld
highrisk
neutropen
patient
deterior
despit
broadspectrum
antibiot
empir
antifung
treatment
initi
even
diagnost
workup
ifd
neg
durat
empir
treatment
short
possibl
longer
resolut
neutropenia
ifd
diagnos
binvas
candida
infect
epidemiolog
neutropen
patient
lifethreaten
infect
lead
acut
dissemin
candidiasi
sepsislik
syndrom
death
chronic
dissemin
candidiasi
hepatosplen
candidiasi
occur
complic
candidemia
neutropen
patient
import
risk
factor
increas
colon
gastrointestin
tract
mucos
surfac
candida
speci
disrupt
protect
mucos
barrier
due
chemotherapi
decreas
phagocyt
capac
due
neutropenia
incid
depend
depth
durat
neutropenia
degre
mucos
disrupt
whether
prophylaxi
administ
recommend
prophylaxi
pleas
see
tabl
often
symptom
candidemia
fever
right
upper
quadrant
discomfort
fever
nausea
elev
liver
enzym
resolut
neutropenia
common
find
chronic
dissemin
candidiasi
cultur
blood
sampl
collect
steril
condit
diagnost
gold
standard
invas
candidiasi
alway
perform
howev
sinc
cultur
hamper
low
sensit
overal
sensit
blood
cultur
estim
around
sever
diagnost
test
develop
betaglucan
cell
wall
constitu
candida
speci
aspergillu
speci
pneumocysti
jirovecii
sever
fungi
betaglucan
detect
plasma
may
detect
case
invas
candidiasi
day
week
prior
posit
blood
cultur
shorten
time
initi
antifung
therapi
howev
posit
result
interpret
caution
low
posit
predict
valu
due
poor
specif
moreov
trueposit
result
specif
invas
candidiasi
rather
suggest
possibl
invas
fungal
infectioncandida
pcr
blood
shown
help
comparison
hamper
lack
standard
fda
approv
commerci
candida
pcr
clinic
data
limit
hepatosplen
candidiasi
contrastenhanc
ct
mri
petct
ultrasound
use
identif
microabscess
liver
spleen
abscess
metastat
embolu
skin
biopsi
sent
microscopi
cultur
pcr
treatment
recommend
antifung
treatment
durat
outlin
tabl
c
invas
aspergillosi
ia
epidemiolog
aspergillu
speci
filament
fungi
ubiquit
environ
inhal
fungal
spore
common
portal
entri
sinopulmonari
diseas
frequent
clinic
manifest
dissemin
occur
hematogen
spread
import
risk
factor
prolong
neutropenia
tcell
impair
patient
high
risk
includ
receiv
induct
therapi
amlmd
especi
refractori
relaps
acut
leukemia
patient
undergo
allogen
hematopoiet
cell
transplant
hct
increas
risk
ia
import
risk
factor
sever
durat
graftversushost
diseas
prevent
includ
reduc
exposur
fungal
spore
hospit
room
higheffici
particular
air
hepa
filtrat
avoid
garden
construct
site
administr
moldact
prophylaxi
patient
high
risk
tabl
diagnost
diagnosi
ia
base
combin
radiolog
microbiolog
find
suscept
host
often
challeng
reach
clinic
present
usual
fever
without
cough
hemoptysi
pleural
pain
thorac
ct
scan
alway
perform
typic
find
includ
nodul
consolid
lesion
wedgeshap
infarct
halo
sign
nodul
cm
diamet
surround
groundglass
opac
reflect
hemorrhag
diagnost
bal
alway
perform
unless
contraind
tabl
sputum
sent
microscopi
cultur
sinc
diagnost
yield
microscopi
cultur
limit
test
develop
avail
test
weak
best
result
report
combin
two
test
galactomannan
gm
antigen
test
use
gm
constitut
part
aspergillu
fungal
wall
detect
serum
bal
csf
commerci
test
fda
approv
neutropen
hematolog
patient
sensit
around
test
serum
higher
bal
patient
receiv
moldact
treatment
sensit
significantli
reduc
aspergillusspecif
lateralflow
devic
antigen
test
perform
similar
gm
advantag
provid
test
result
within
minut
well
document
betaglucan
see
also
section
invas
candida
infect
sensit
similar
one
gm
poor
specif
due
high
rate
falseposit
result
trueposit
test
specif
aspergillu
speci
commerci
test
avail
fda
approvalpcr
blood
bal
shown
diagnost
perform
compar
gm
combin
neg
gm
pcr
test
bal
perform
patient
receiv
moldact
treatment
high
neg
predict
valu
howev
recent
pcr
assay
standard
valid
sinc
assay
approv
fda
difficult
recommend
pcr
routin
use
yet
treatment
firstlin
treatment
voriconazol
isavuconazol
isavuconazol
gener
better
toler
therapeut
drug
monitor
gener
recommend
use
moldact
azol
make
sure
therapeut
level
reach
altern
treatment
lipid
formul
amphotericin
b
primari
therapi
combin
voriconazol
echinocandin
may
consid
patient
sever
diseas
especi
profound
prolong
neutropenia
clinic
cours
depend
durat
sever
neutropenia
size
lesion
usual
increas
week
treatment
remain
stabl
anoth
week
repetit
ct
scan
recommend
week
start
treatment
unless
clinic
deterior
seen
treatment
durat
minimum
week
depend
underli
diseas
immunodefici
patient
requir
subsequ
immunosuppress
receiv
secondari
prophylaxi
prevent
recurr
adjunct
measur
consid
ongo
immunosuppress
minim
elimin
altogeth
possibl
colonystimul
factor
may
consid
neutropen
patient
granulocyt
transfus
may
consid
refractori
infect
dother
mold
infect
import
epidemiolog
mold
ia
seen
around
invas
mold
infect
either
alon
combin
ia
formerli
known
zygomycosi
caus
member
order
mucoral
domin
etiolog
nonia
mold
infect
mucormycosi
aggress
report
mortal
rate
caus
invas
infect
fusarium
speci
second
common
nonia
mold
infect
outcom
usual
poor
larg
depend
recoveri
immun
statu
host
particularli
neutropenia
risk
factor
nonia
mold
infect
ia
ie
prolong
neutropenia
tcell
suppressiondiagnost
common
manifest
rhinocerebr
pulmonari
infect
diagnost
reli
radiolog
combin
microscopi
cultur
biopsi
bal
pcr
may
consid
commerci
test
approv
fda
exist
typic
find
ct
scan
ia
except
revers
halo
sign
area
groundglass
opac
surround
ring
consolid
frequent
mucormycosi
thu
suggest
diseas
neg
gm
aspergillu
pcr
bal
perform
suspicion
mold
infect
also
suggest
nonia
infect
mucormycosi
fusariosi
hematolog
patient
often
dissemin
pulmonari
lesion
found
almost
case
radiolog
pictur
similar
ia
nodular
papular
skin
lesion
biopsi
common
blood
cultur
often
posit
fusarium
speci
interact
gm
test
test
may
becom
posit
even
absenc
concomit
ia
treatment
aggress
infect
hematolog
patient
treatment
must
initi
promptli
firstlin
agent
highdos
liposom
amphotericin
b
combin
surgeri
isavuconazol
recent
evalu
retrospect
found
efficaci
similar
liposom
amphotericin
b
option
liposom
amphotericin
b
use
surgeri
perform
possibl
drug
choic
treatment
invas
fusariosi
either
voriconazol
liposom
amphotericin
b
epneumocysti
jirovecii
pneumonia
pcp
epidemiolog
transmiss
pneumocysti
jirovecii
occur
first
year
life
via
persontoperson
contact
usual
asymptomat
mild
infect
upper
respiratori
tractp
jirovecii
pneumonia
pcp
pjp
carri
high
mortal
hematolog
patient
earli
recognit
treatment
critic
success
outcom
pcp
occur
previou
colon
new
persontoperson
transmiss
prophylaxi
administ
patient
risk
acut
lymphoblast
leukemia
allogen
hct
week
treatment
corticosteroid
mgday
prednison
treatment
alemtuzumab
treatment
fludarabinecyclophosphamiderituximab
prophylaxi
also
consid
patient
risk
factor
treatment
lymphoma
firstlin
prophylaxi
tmpsmx
secondlin
choic
includ
aerosol
pentamidin
dapson
atovaquon
diagnost
clinic
present
often
fever
nonproduct
cough
dyspnea
andor
impair
oxygen
chest
xray
low
sensit
thorac
ct
scan
usual
show
bilater
patchi
groundglass
opac
predominantli
perihilar
region
howev
radiolog
find
nonspecif
establish
diagnosi
pcp
pathogen
must
identifi
identif
p
jirovecii
difficult
hematolog
patient
gener
lower
fungal
load
nonhematolog
patient
bal
prefer
specimen
sinc
gradient
fungal
load
expect
highest
load
bal
fluid
lowest
upper
respiratori
sampl
addit
bal
identifi
pathogen
import
sinc
coinfect
common
patient
pcp
bal
perform
sputum
prefer
induc
sputum
prefer
upper
respiratori
specimen
oral
wash
nasopharyng
swab
nasal
swab
p
jirovecii
cultiv
identif
base
pcr
microscopi
use
immunofluoresc
techniqu
pcr
higher
sensit
posit
result
may
difficult
reliabl
discrimin
colon
infect
posit
correspond
diagnos
pcp
regardless
specimen
pcp
rule
pcr
neg
bal
wherea
neg
pcr
test
sputum
upper
respiratori
sampl
rule
infect
combin
posit
pcr
neg
distinguish
colon
infect
neg
test
serum
betaglucan
high
neg
predict
valu
treatment
treatment
institut
promptli
optim
chanc
success
outcom
firstlin
treatment
highdos
iv
tmpsmx
day
follow
prophylaxi
immunosuppress
resolv
secondlin
treatment
includ
oral
primaquin
iv
oral
clindamycin
iv
pentamidin
oral
atovaquon
administr
glucocorticoid
gener
recommend
must
base
casebycas
basi
aepidemiolog
broadli
divid
latentpersist
virus
primari
infect
remain
patient
mani
yearsfor
life
virus
present
short
period
viral
infect
particularli
import
immunocompromis
especi
allogen
hct
mani
differ
virus
caus
clinic
syndrom
tabl
therefor
specif
diagnost
procedur
requir
allow
correct
managementbdiagnosi
detect
antibodi
detect
antibodi
evid
infect
standard
techniqu
healthi
immun
compet
individu
igm
sign
recent
infect
igg
evid
past
infect
hematolog
patient
serolog
rare
use
diagnosi
ongo
infect
import
determin
risk
viral
infect
occur
posttransplant
detect
virus
viral
compon
tradit
viru
isol
cell
cultur
rare
perform
today
instead
method
detect
viral
antigen
nucleic
acid
nucleic
acid
test
nat
becom
standard
viru
identif
nat
also
use
determin
viral
load
mutat
analysissequenc
detect
resist
antivir
drug
diagnosi
tissu
diagnos
endorgan
diseas
viru
detect
affect
organ
prefer
specif
stain
tissu
cherpesvirus
latentpersist
virus
frequent
reactiv
immunosuppress
patient
herp
simplex
viru
hsv
rate
seroposit
popul
increas
age
usual
caus
local
infect
orofaci
area
occur
locat
usual
caus
local
infect
urogenit
tract
enceph
sever
manifest
rare
hematolog
patient
normal
popul
caus
mening
nat
diagnost
method
choic
virus
prophylaxi
acyclovirvalaciclovir
recommend
seroposit
patient
undergo
hsct
consid
intens
treat
hematolog
patient
drug
also
first
choic
treatment
resist
acyclovir
develop
occur
approxim
patient
depend
risk
profil
foscarnet
firstlin
treatment
acyclovirresist
viru
dcytomegaloviru
cmv
e
rate
cmv
seroposit
increas
age
vari
geograph
locat
seroposit
risk
factor
nonrelaps
mortal
decreas
surviv
allogen
hct
cmvseroneg
donor
avail
use
cmvseroneg
patient
f
approxim
cmvseroposit
patient
develop
activ
cmv
infect
hsct
commonli
first
month
risk
cmvseroneg
patient
receiv
graft
cmvseroposit
donor
approxim
hematolog
patient
patient
undergo
autolog
hsct
risk
much
lower
patient
receiv
antitcel
therapi
increas
risk
g
cmv
infect
asymptomat
caus
lowgrad
fever
possibl
depress
bone
marrow
function
endorgan
cmv
diseas
occur
hsct
patient
commonli
gastrointestin
diseas
cmv
pneumonia
still
associ
high
mortal
endorgan
manifest
retin
hepat
enceph
risk
factor
allogen
hct
acut
gvhd
intens
tcell
suppress
cmv
endorgan
diseas
group
hematolog
patient
uncommon
h
weekli
blood
monitor
allogen
hct
patient
recommend
use
either
quantit
pcr
antigenemia
assay
fix
cutoff
recommend
sinc
depend
risk
profil
patient
exact
assay
use
mani
center
use
cutoff
around
iuml
monitor
routin
recommend
autolog
hct
patient
hematolog
patient
inform
regard
cutoff
therapi
type
patient
j
diagnosi
cmv
diseas
requir
symptom
andor
sign
cmv
detect
involv
organ
cmv
blood
combin
symptom
organ
enough
make
diagnosi
cmv
diseas
k
possibl
strategi
manag
prophylaxi
preemptiv
therapi
treatment
endorgan
diseas
l
shown
effect
prophylaxi
reduc
risk
clinic
signific
cmv
infect
also
reduc
allcaus
mortal
preemptiv
therapi
base
detect
cmv
monitor
effect
strategi
highrisk
patient
allogen
hct
recipi
ganciclovir
valganciclovir
firstlin
drug
treatment
cmv
infect
diseas
highdos
iv
immunoglobulin
ig
use
combin
ganciclovir
treatment
cmv
pneumonia
use
proven
studi
n
antivir
resist
develop
patient
depend
risk
profil
secondlin
drug
foscarnet
cidofovir
main
limit
drug
side
effect
case
report
small
case
seri
exist
use
leflunomid
artesun
resist
refractori
cmv
cmv
specif
tcell
option
avail
p
new
antivir
current
undergo
clinic
develop
maribavir
letermovir
brincidofovir
evaricellazost
viru
vzv
vzv
caus
differ
diseas
primari
vzv
infect
caus
chickenpox
reactiv
caus
herp
zoster
hz
shingl
countri
use
gener
vaccin
children
individu
experienc
chickenpox
childhood
becom
sever
immunocompromis
individu
risk
hz
increas
age
also
increas
immunocompromis
individu
hz
case
selflimit
give
local
symptom
howev
dissemin
infect
mimick
primari
varicella
viscer
case
sometim
without
skin
rash
occur
poor
outcom
unless
rapidli
diagnos
treat
case
easili
recogn
characterist
rash
pcr
vesicular
rash
diagnost
method
choic
immunofluoresc
might
also
use
pcr
blood
use
diagnosi
viscer
case
valacyclovir
drug
choic
prevent
treatment
vzv
infect
prophylaxi
recommend
patient
high
risk
hz
hsct
recipi
myeloma
patient
treat
proteasom
inhibitor
iv
acyclovir
given
patient
primari
varicella
dissemin
viscer
hz
case
manag
sever
local
hz
zoster
ophthalmicu
zoster
oticu
need
close
collabor
appropri
specialist
fepsteinbarr
viru
ebv
rate
seroposit
increas
age
adult
seroposit
ebv
constantli
replic
seroposit
individu
without
caus
symptom
endorgan
ebv
diseas
includ
mening
hepat
pneumonia
occur
rare
also
sever
immunocompromis
individu
import
complic
ebv
posttranspl
lymphoprolif
diseas
ptld
occur
highrisk
allogen
hct
recipi
ebv
also
trigger
hemophagocyt
lymphohistiocytosi
hlh
patient
hematolog
malign
highrisk
allogen
hct
patient
monitor
blood
quantit
pcr
indic
establish
cutoff
sinc
standard
test
symptom
sign
ptld
unspecif
increas
ldh
lymphadenopathi
fever
common
ct
scan
detect
splenomegali
andor
intrathorac
intraabdomin
lymphadenopathi
consid
biopsi
lymph
node
need
prove
diagnosi
specif
antivir
therapi
effect
ebv
rituximab
prefer
intervent
preemptiv
therapi
ebv
ptld
base
increas
ebv
viral
load
treatment
establish
ptld
reduct
immunosuppress
attempt
possibl
ebvspecif
tcell
option
avail
gother
herpesvirus
human
herpesvirus
hhv
b
common
caus
cerebrospin
fluid
avail
antivir
drug
treatment
foscarnet
ganciclovirvalganciclovir
hcommunityacquir
respiratori
virus
respiratori
virus
circul
commun
risk
patient
hematolog
diseas
becom
infect
reflect
local
epidemiolog
respiratori
syncyti
viru
rsv
influenza
virus
adenovirus
best
known
abl
caus
diseas
hematolog
patient
report
sever
diseas
also
report
mani
respiratori
virus
includ
parainfluenza
virus
metapneumovirus
rhinovirus
nosocomi
spread
occur
infect
control
paramount
infect
mild
selflimit
sever
infect
occur
especi
allogen
hct
recipi
patient
receiv
intens
immunosuppress
therapi
diagnosi
center
base
multiplex
pcr
respiratori
sampl
either
upper
airway
nasal
nasopharyng
throat
sampl
lower
respiratori
tract
bal
fluid
exist
assay
detect
differ
respiratori
virus
techniqu
use
antigen
test
immunofluoresc
limit
import
detect
one
viru
import
part
manag
prevent
includ
avoid
infect
individu
handwash
influenza
vaccin
patient
famili
member
staff
recogn
infect
spread
individu
limit
symptom
allogen
hct
candid
present
start
condit
symptomat
infect
respiratori
viru
postpon
transplant
consid
antivir
therapi
limit
role
patient
consid
sever
immunocompromis
patient
allogen
hct
patient
therapeut
option
data
support
efficaci
although
control
studi
ribavirin
rsv
neuraminidas
inhibitor
influenza
cidofovirbrincidofovir
adenoviru
infect
ihepat
virusessever
differ
virus
caus
liver
diseas
hematolog
patient
import
hepat
b
c
virus
signific
pathogen
patient
hematolog
diseas
screen
alway
perform
increas
evid
implic
hepat
e
viru
hev
import
pathogen
viru
transmit
blood
product
hepat
b
viru
hbv
hbv
infect
wide
distribut
world
vari
preval
differ
popul
chronic
infect
associ
liver
cirrhosi
develop
hepatocellular
cancer
immunosuppress
therapi
associ
hbv
reactiv
chronic
infect
individu
hbv
reactiv
result
sever
liver
diseas
includ
liver
failur
reactiv
common
hbsagposit
individu
also
hbsagneg
individu
antihbcposit
individu
receiv
intens
immunosuppress
hsct
antibcel
antibodi
reactiv
hbv
patient
high
risk
reactiv
receiv
antivir
prophylaxi
hbv
hepat
c
viru
hcv
hcv
infect
wide
distribut
world
vari
preval
differ
popul
hcv
infect
associ
increas
risk
nonhodgkin
lymphoma
chronic
hcv
infect
associ
liver
cirrhosi
hepatocellular
cancer
chronic
infect
patient
hcv
flareup
liver
diseas
immunosuppress
therapi
liver
monitor
therefor
indic
antivir
therapi
hcv
infect
rapidli
evolv
expert
advic
regard
treatment
option
therefor
obtain
jother
virusesmani
differ
virus
caus
symptomat
infect
hematolog
patient
includ
polyomavirus
jc
bk
virus
caus
gastroenter
outbreak
noroviru
rotaviru
virus
spread
mosquito
bite
yellow
fever
dengu
zika
chikungunya
knowledg
clinic
import
virus
limit
like
sever
diseas
develop
sever
immunocompromis
patient
earli
diagnosi
specif
treatment
key
factor
reduc
morbid
mortal
infect
hematolog
hct
patient
rise
multiresist
organ
major
threat
infect
control
therefor
uttermost
import
